03/12/2024
N. Kudryashova, B. Shulgin, N. Katuninks, V. Kulesh, G. Helmlinger, K. Zhudenkov, K. Peskov. (2024) Assessment of NSCLC disease burden: A survival model-based meta-analysis study. Comput Struct Biotechnol J. 2024, 24:611-621. https://www.csbj.org/article/S2001-0370(24)00300-3/fulltext
We present a meta-analytic approach to quantify the disease burden of NSCLC using integrative survival models. Aggregated survival data from open sources were used to parameterize models for early and advanced NSCLC, incorporating chemotherapy, targeted therapy, and immunotherapy. Modeling showed that the introduction of new treatments in the subset of patients with advanced NSCLC increased median survival by 8.1 months. This integrative modeling platform aimed at characterizing cancer burden enables us to accurately quantify the cumulative benefits of introducing tailored treatments into treatment regimens and prolonging survival when the disease is detected early.
